NCT04453033Completed
DB RCT for Specialized Phototherapy in Parkinson's Disease.
Double-blind, Randomized Controlled Trial to Demonstrate Efficacy of Celeste® Specialized Phototherapy in Treating Parkinson's Disease.
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 350 (actual)
- First submitted
- 26 Jun 2020
- Start date
- 26 Feb 2024
- Primary completion date
- 30 May 2026
- Lead sponsor
- PhotoPharmics, Inc.
- Diseases
- Parkinson disease
- NCT number
- NCT04453033
What you commit to
- Study type: Interventional
- Participants enrolled: 350
- From 26 Feb 2024 to the primary completion date, 30 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- An anticipated need for a change in dopamine replacement therapy, concomitant medications, OTC/supplements, or other alternative therapies during the participant's involvement in the investigation
- History of previous light therapy use for PD
Other illness
- Diagnosis of an atypical Parkinsonian syndrome
Other
- Significant OFF state or bothersome dyskinesias that in the judgment of the rater, would interfere with participation in the study.
- \-
Who the study is looking for
- Diagnosis of Parkinson's disease as determined by the study PI, in keeping with the UK PD Society Brain Bank Criteria for the Diagnosis of PD
- Responsiveness to dopaminergic medication, as judged by the rater, and have been using treatment for at least the past 1 year
- Relatively good eyesight as attested to by participants (Corrective lenses of at least 20/60)
- Stable levodopa and other anti-PD medications for at least 28 days prior to screening -
Age in the registry: 45 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.